Format
Sort by
    Items per page

    Send to

    Choose Destination

    Links from PubMed

    Items: 1 to 20 of 223

    1.

    177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy.

    Garkavij M, Nickel M, Sjögreen-Gleisner K, Ljungberg M, Ohlsson T, Wingårdh K, Strand SE, Tennvall J.

    Cancer. 2010 Feb 15;116(4 Suppl):1084-92. doi: 10.1002/cncr.24796.

    2.

    Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment.

    Sandström M, Garske-Román U, Granberg D, Johansson S, Widström C, Eriksson B, Sundin A, Lundqvist H, Lubberink M.

    J Nucl Med. 2013 Jan;54(1):33-41. doi: 10.2967/jnumed.112.107524. Epub 2012 Dec 7.

    3.

    A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.

    Konijnenberg MW, Bijster M, Krenning EP, De Jong M.

    J Nucl Med. 2004 Jul;45(7):1260-9. Erratum in: J Nucl Med. 2009 Dec;50(12):2092.

    4.

    Practical aspects of peptide receptor radionuclide therapy with [177Lu][DOTA0, Tyr3]octreotate.

    Bakker WH, Breeman WA, Kwekkeboom DJ, De Jong LC, Krenning EP.

    Q J Nucl Med Mol Imaging. 2006 Dec;50(4):265-71. Review.

    5.

    Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.

    Ilan E, Sandström M, Wassberg C, Sundin A, Garske-Román U, Eriksson B, Granberg D, Lubberink M.

    J Nucl Med. 2015 Feb;56(2):177-82. doi: 10.2967/jnumed.114.148437. Epub 2015 Jan 15.

    6.

    Up-regulation of somatostatin receptor density on rat CA20948 tumors escaped from low dose [177Lu-DOTA0,Tyr3]octreotate therapy.

    Melis M, Forrer F, Capello A, Bijster M, Bernard BF, Reubi JC, Krenning EP, De Jong M.

    Q J Nucl Med Mol Imaging. 2007 Dec;51(4):324-33.

    7.

    Effect of calculation method on kidney dosimetry in 177Lu-octreotate treatment.

    Heikkonen J, Mäenpää H, Hippeläinen E, Reijonen V, Tenhunen M.

    Acta Oncol. 2016 Sep - Oct;55(9-10):1069-1076. doi: 10.1080/0284186X.2016.1182642. Epub 2016 May 24.

    PMID:
    27219529
    8.

    Estimation of absorbed dose to the kidneys in patients after treatment with 177Lu-octreotate: comparison between methods based on planar scintigraphy.

    Larsson M, Bernhardt P, Svensson JB, Wängberg B, Ahlman H, Forssell-Aronsson E.

    EJNMMI Res. 2012 Sep 24;2(1):49. doi: 10.1186/2191-219X-2-49.

    9.

    Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate.

    Valkema R, Pauwels SA, Kvols LK, Kwekkeboom DJ, Jamar F, de Jong M, Barone R, Walrand S, Kooij PP, Bakker WH, Lasher J, Krenning EP.

    J Nucl Med. 2005 Jan;46 Suppl 1:83S-91S.

    10.

    Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide.

    Barone R, Walrand S, Konijnenberg M, Valkema R, Kvols LK, Krenning EP, Pauwels S, Jamar F.

    Nucl Med Commun. 2008 Mar;29(3):283-90. doi: 10.1097/MNM.0b013e3282f3d03e.

    PMID:
    18349800
    11.

    Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.

    De Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WA, Bakker WH, Smith C, Pauwels S, Krenning EP.

    Semin Nucl Med. 2002 Apr;32(2):133-40. Review.

    PMID:
    11965608
    12.

    Peptide receptor radionuclide therapy with (177)Lu labeled somatostatin analogs DOTATATE and DOTATOC: contrasting renal dosimetry in the same patient.

    Kulkarni HR, Schuchardt C, Baum RP.

    Recent Results Cancer Res. 2013;194:551-9. doi: 10.1007/978-3-642-27994-2_32.

    PMID:
    22918782
    13.

    Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship.

    Barone R, Borson-Chazot F, Valkema R, Walrand S, Chauvin F, Gogou L, Kvols LK, Krenning EP, Jamar F, Pauwels S.

    J Nucl Med. 2005 Jan;46 Suppl 1:99S-106S.

    14.

    The Bad Berka dose protocol: comparative results of dosimetry in peptide receptor radionuclide therapy using (177)Lu-DOTATATE, (177)Lu-DOTANOC, and (177)Lu-DOTATOC.

    Schuchardt C, Kulkarni HR, Prasad V, Zachert C, Müller D, Baum RP.

    Recent Results Cancer Res. 2013;194:519-36. doi: 10.1007/978-3-642-27994-2_30.

    PMID:
    22918780
    15.

    Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate.

    Khan S, Krenning EP, van Essen M, Kam BL, Teunissen JJ, Kwekkeboom DJ.

    J Nucl Med. 2011 Sep;52(9):1361-8. doi: 10.2967/jnumed.111.087932. Epub 2011 Jul 27.

    16.

    Implementation and evaluation of patient-specific three-dimensional internal dosimetry.

    Kolbert KS, Sgouros G, Scott AM, Bronstein JE, Malane RA, Zhang J, Kalaigian H, McNamara S, Schwartz L, Larson SM.

    J Nucl Med. 1997 Feb;38(2):301-8.

    17.

    Long-Term Retention of 177Lu/177mLu-DOTATATE in Patients Investigated by γ-Spectrometry and γ-Camera Imaging.

    Gleisner KS, Brolin G, Sundlöv A, Mjekiqi E, Östlund K, Tennvall J, Larsson E.

    J Nucl Med. 2015 Jul;56(7):976-84. doi: 10.2967/jnumed.115.155390. Epub 2015 May 21.

    18.

    Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate.

    de Keizer B, van Aken MO, Feelders RA, de Herder WW, Kam BL, van Essen M, Krenning EP, Kwekkeboom DJ.

    Eur J Nucl Med Mol Imaging. 2008 Apr;35(4):749-55. doi: 10.1007/s00259-007-0691-z. Epub 2008 Jan 16.

    19.

    Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer.

    Delker A, Fendler WP, Kratochwil C, Brunegraf A, Gosewisch A, Gildehaus FJ, Tritschler S, Stief CG, Kopka K, Haberkorn U, Bartenstein P, Böning G.

    Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):42-51. doi: 10.1007/s00259-015-3174-7. Epub 2015 Aug 29.

    PMID:
    26318602
    20.

    Individualized dosimetry in patients undergoing therapy with (177)Lu-DOTA-D-Phe (1)-Tyr (3)-octreotate.

    Sandström M, Garske U, Granberg D, Sundin A, Lundqvist H.

    Eur J Nucl Med Mol Imaging. 2010 Feb;37(2):212-25. doi: 10.1007/s00259-009-1216-8. Epub 2009 Sep 2.

    PMID:
    19727718

    Supplemental Content

    Support Center